Conv. Plasma
Nigella Sativa

All ivermectin studies
Meta analysis
study COVID-19 treatment researchIvermectinIvermectin (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   

Study of the Efficacy and Safety of Topical Ivermectin + Iota-Carrageenan in the Prophylaxis against COVID-19 in Health Personnel

Carvallo et al., Journal of Biomedical Research and Clinical Investigation, doi:10.31546/2633-8653.1007
Nov 2020  
  Source   PDF   All Studies   Meta AnalysisMeta
Case 100% Improvement Relative Risk Ivermectin for COVID-19  Carvallo et al.  Prophylaxis Does ivermectin + iota-carrageenan reduce COVID-19 infections? Prospective study of 1,195 patients in Argentina Fewer cases with ivermectin + iota-carrageenan (p<0.000001) Carvallo et al., J. Biomedical Researc.., Nov 2020 Favorsivermectin Favorscontrol 0 0.5 1 1.5 2+
Ivermectin for COVID-19
4th treatment shown to reduce risk in August 2020
*, now with p < 0.00000000001 from 104 studies, recognized in 22 countries.
No treatment is 100% effective. Protocols combine treatments. * >10% efficacy, ≥3 studies.
4,300+ studies for 75 treatments.
Prophylaxis study using ivermectin and iota-carrageenan showing 0 of 788 cases from treated healthcare workers, compared to 237 of 407 control.
See1 for discussion of issues with this trial.
5 studies use direct respiratory tract administration2-6
Targeted administration to the respiratory tract provides treatment directly to the typical source of initial SARS-CoV-2 infection and replication, and allows for rapid onset of action, higher local drug concentration, and reduced systemic side effects.
This is the 20th of 104 COVID-19 controlled studies for ivermectin, which collectively show efficacy with p<0.0000000001 (1 in 1 sextillion).
51 studies are RCTs, which show efficacy with p=0.00000015.
This study is excluded in the after exclusion results of meta analysis: concern about potential data issues.
Study covers iota-carrageenan and ivermectin.
risk of case, 99.9% lower, RR 0.001, p < 0.001, treatment 0 of 788 (0.0%), control 237 of 407 (58.2%), NNT 1.7, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm).
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Carvallo et al., 17 Nov 2020, prospective, Argentina, peer-reviewed, 4 authors, dosage 12mg weekly, this trial uses multiple treatments in the treatment arm (combined with iota-carrageenan) - results of individual treatments may vary.
This PaperIvermectinAll
Study of the Efficacy and Safety of Topical Ivermectin + Iota-Carrageenan in the Prophylaxis against COVID-19 in Health Personnel
Carvallo Héctor, Hirsch Roberto, Alkis Psaltis, Contreras Veronica
Journal of Biomedical Research and Clinical Investigation, doi:10.31546/2633-8653.1007
The severe acute respiratory syndrome-coronavirus-2 pandemic has had devastating health and socio-economic implications worldwide. Epidemiologic data indicate that SARS-CoV2 is spread by respiratory droplets and contact. The lack of acquired human immunity to the virus and the absence of a vaccine, has meant that current management strategies aimed at virus containment through mask wearing, social distancing and enforced lockdowns. Although the World Health Organization recommends 1,5 meters distancing to minimize transmission, recent studies have demonstrated high stability in aerosols and transmission distances up to 10 meters from emission sources . Health care workers are at particular risk from SARS-CoV-2. At present, no reliable prophylactic therapy exists to minimize their risk of acquiring SARS-CoV-2, and so they rely solely upon hand hygiene and the wearing of appropriate personal protective equipment (PPE), which is often in limited supply. Several studies have shown that the salivary gland and tongue express the ACE2 receptor, suggesting that the oral cavity is a perfect host for the invasion of COVID. Theoretically, agents that can inhibit viral adhesion and replication within the primary sites of viral entry (the nasal and oral cavity), may have a role in preventing SARS-CoV-2 transmission. Use of these agents prophylactically, would be especially beneficial in health care workers, particularly given the delay in results from viral RNA detection diagnostic test and the fact that many infected patients may have mild or no symptoms of the virus in the early stages. Two possible substances have been identified as candidate prophylactic agents in the fight against SARS-CoV-2. Carrageenans are naturally occurring extracts from the Rhodophyceas seaweed. Recently, the viricidal capacity of carrageenan has been reported, through inhibition of viral-host cell adhesion and early replication. Iota-carrageenan demonstrates potent antiviral activity in vitro, reducing rhinovirus, herpes simplex virus and the Japanese encephalitis virus reproduction and their cytopathic effects. Similarly, ivermectin has also been shown to posess antiviral activity against a whole host of RNA viruses (Zika, dengue, yellow fever, human immunodeficiency virus type 1). Thus, the combination of both products can provide an extra protection for those at risk of contagion.
Conflicts of Interest: The authors declare no conflict of interest.
Andersen, Rambaut, Lipkin, The proximal origin of SARS-CoV-2, Nat Med
Angulo, Efficacy of ivermectin in the treatment of children parasitized by Strongyloides stercoralis, Biomedica
Baraka, Mahmoud, Marschke, Ivermectin distribution in the plasma and tissues of patients infected with Onchocerca volvulus, Eur J Clin Pharmacol, doi:10.1007/s002280050131
Carvallo, Hirsch, Ivermectin, aspirin, dexametasone and enoxaparin as treatment for COVID 19, J Am Med Assoc
Ceccotti, El COVID-19
Chen, Jiajia, Jinfeng, Detection of 2019-nCoV in Saliva and Characterization of Oral Symptoms in COVID-19 Patients, Cell Prolif, doi:10.1111/cpr.12923
Chen, Wu, Guo, Clinical and immunological features of severe and moderate coronavirus disease 2019, J Clin Invest
Cynthia, Arturo, Safety, Tolerability, and Pharmacokinetics of Escalating High Doses of Ivermectin in Healthy Adult Subjects, J Clin Pharmacol, doi:10.1177/009127002237994?sid=nlm%3Apubmed
Edwards, Dingsdale, Helsby, The Relative Systemic Availability of Ivermectin after Administration as capsule, tablet, and Oral Solution, Eur J Clin Pharmacol, doi:10.1007/BF00637608
Emma, Ruth, Susan, Virucidal Activity of Polysaccharide Extracts from Four Algal Species against Herpes Simplex Virus, Antiviral Res
Giovannoni, Rol antiviral intrinseco de PML en la infección con flavivirus
Hamming, Timens, Bulthuis, Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis, J Pathol, doi:10.1002/path.1570
Kai-Wang, Tak-Yin, Wai-Shing, Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study, Lancet Infect Dis
Lagerlo, Dawes, The volume of saliva in the mouth before and after swallowing, J Dent Res, doi:10.1177/00220345840630050201?url_ver=Z39.88-2003&
Leon, Julian, Mike, The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro, Antiviral Res
Liu, Wei, Alvarez, Epithelial cells lining salivary gland ducts are early target cells of severe acute respiratory syndrome coronavirus infection in the upper respiratory tracts of Rhesus macaques, J Virol
Martin, Thomas, Angelika, Carrageenan nasal spray in virus confirmed common cold: individual patient data analysis of two randomized controlled trials, Multidiscip Respir Med, doi:10.1186/2049-6958-9-57
Mehta, Mcauley, Brown, COVID-19: consider cytokine storm syndromes and immunosuppression, Lancet
Mitchell, William, Douglas, West Nile Virus Infection in Reindeer (Rangifer Tarandus), J Vet Diagn Invest, doi:10.1177/104063870401600307?url_ver=Z39.88-2003&
Recalcati, Cutaneous manifestations in COVID-19: a first perspective, J Eur Acad Dermatol Venereol, doi:10.1111/jdv.16387
Rodríguez, Cardona, Clinical, laboratory and imaging features of COVID-19: A systematic review and meta-analysis, Travel Med Infect Dis
Ruiz Esquide Canale, Weil, Turienzo, Infección por virus Zika y sus manifestaciones cutáneas, Arch Arg Dermatol
Santosh, Parmar, Anand, A Review of Salivary Diagnostics and Its Potential Implication in Detection of Covid-19, Cureus
Tp De Castro, Duarte, Carvalho, Estudo preliminar sobre os efeitos clínicos do tratamento da Febre Chikungunya aguda usando Ivermectina como fármaco antiviral, AMPE
Wang, Chen, Liu, Detection of SARS associated coronavirus in throat wash and saliva in early diagnosis, Emerg Infect Dis
Xu, Zhong, Deng, High expression of ACE2 receptor of 2019-nCoV on the epithelial cells of oral mucosa, Int J Oral Sci
{ 'indexed': {'date-parts': [[2024, 1, 30]], 'date-time': '2024-01-30T00:20:35Z', 'timestamp': 1706574035457}, 'reference-count': 0, 'publisher': 'Medical Press Open Access', 'issue': '1', 'content-domain': {'domain': [], 'crossmark-restriction': False}, 'published-print': {'date-parts': [[2020, 11, 17]]}, 'DOI': '10.31546/2633-8653.1007', 'type': 'journal-article', 'created': { 'date-parts': [[2020, 11, 18]], 'date-time': '2020-11-18T14:51:47Z', 'timestamp': 1605711107000}, 'source': 'Crossref', 'is-referenced-by-count': 21, 'title': 'Study of the Efficacy and Safety of Topical Ivermectin + Iota-Carrageenan in the Prophylaxis ' 'against COVID-19 in Health Personnel', 'prefix': '10.31546', 'volume': '2', 'author': [ {'given': 'Carvallo', 'family': 'Héctor', 'sequence': 'first', 'affiliation': []}, {'given': 'Hirsch', 'family': 'Roberto', 'sequence': 'additional', 'affiliation': []}, {'given': 'Alkis', 'family': 'Psaltis', 'sequence': 'additional', 'affiliation': []}, {'given': 'Contreras', 'family': 'Veronica', 'sequence': 'additional', 'affiliation': []}], 'member': '16574', 'published-online': {'date-parts': [[2020, 11, 17]]}, 'container-title': 'Journal of Biomedical Research and Clinical Investigation', 'original-title': [], 'link': [ { 'URL': '', 'content-type': 'unspecified', 'content-version': 'vor', 'intended-application': 'similarity-checking'}], 'deposited': { 'date-parts': [[2021, 8, 23]], 'date-time': '2021-08-23T15:38:50Z', 'timestamp': 1629733130000}, 'score': 1, 'resource': {'primary': {'URL': ''}}, 'subtitle': [], 'short-title': [], 'issued': {'date-parts': [[2020, 11, 17]]}, 'references-count': 0, 'journal-issue': { 'issue': '1', 'published-online': {'date-parts': [[2020, 11, 17]]}, 'published-print': {'date-parts': [[2020, 11, 17]]}}, 'URL': '', 'relation': {}, 'container-title-short': 'J. biomed. res. clin. investig.', 'published': {'date-parts': [[2020, 11, 17]]}}
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop